For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.
Population Health Sciences

You are here

Publications

Found 33 results
Author [ Title(Asc)] Type Year
Filters: First Letter Of Last Name is O  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Frey MK, Kahn RM, Chapman-Davis E, Tubito F, Pires M, Christos P, Anderson S, Mukherjee S, Jordan B, Blank SV et al..  2020.  Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.. J Clin Oncol. 38(13):1389-1397.
Shoag J, Liu D, Ma X, Oromendia C, Christos P, Ballman K, Angulo C, Cai PY, Gaffney C, Klein E et al..  2020.  Prognostic value of the SPOP mutant genomic subclass in prostate cancer.. Urol Oncol.
Brown B, O'Donnell E, Casalino LP.  2019.  Private Equity Investment in Behavioral Health Treatment Centers.. JAMA Psychiatry.
Casalino LP, Saiani R, Bhidya S, Khullar D, O'Donnell E.  2019.  Private Equity Acquisition of Physician Practices.. Ann Intern Med. 171(1):78.
Awad SF, O'Flaherty M, El-Nahas KG, Al-Hamaq AO, Critchley JA, Abu-Raddad LJ.  2019.  Preventing type 2 diabetes mellitus in Qatar by reducing obesity, smoking, and physical inactivity: mathematical modeling analyses.. Popul Health Metr. 17(1):20.
Press MJ, Gerber LM, Peng TR, Pesko MF, Feldman PH, Ouchida K, Sridharan S, Bao Y, Barron Y, Casalino LP.  2015.  Post-Discharge Communication Between Home Health Nurses and Physicians: Measurement, Quality, and Outcomes.. J Am Geriatr Soc. 63(7):1299-305.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Batra JS, Niaz MJunaid, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM et al..  2020.  Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer.. Urol Oncol.
Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ et al..  2019.  Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ( Lu-J591) for metastatic castration-resistant prostate cancer.. Cancer. 125(15):2561-2569.